newsfilter
← Latest News
Business Wire·

Satellos Reports 2024 Financial Results and Highlights Company Progress

– Completed enrollment and dosing in a Phase 1a clinical trial in 72 healthy volunteers to assess safety and pharmacokinetic (PK) properties of SAT-3247 – Presented initial Phase 1a data at Muscular Dystrophy